{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tariquidar",
    "query": {
      "intervention": "Tariquidar"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T02:52:12.011Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04603066",
      "title": "Tariquidar-ondansetron Combination in Neuropathic Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuropathic Pain"
      ],
      "interventions": [
        {
          "name": "Ondansetron 16 mg with Tariquidar",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron 16 mg with Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-01-31",
      "completion_date": "2023-11-03",
      "has_results": true,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-09-06T02:52:12.011Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04603066"
    },
    {
      "nct_id": "NCT00071058",
      "title": "Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adrenal Cortex Neoplasms"
      ],
      "interventions": [
        {
          "name": "XR9576 (Tariquidar)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2003-10",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2012-09-18",
      "last_synced_at": "2026-09-06T02:52:12.011Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071058"
    },
    {
      "nct_id": "NCT00011414",
      "title": "Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wilms' Tumor",
        "Sarcoma",
        "Adenaocortical Carcinoma",
        "Refractory Cancer",
        "Coldrhood Cancer"
      ],
      "interventions": [
        {
          "name": "Tariquidar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 29,
      "start_date": "2001-02-15",
      "completion_date": "2016-01-13",
      "has_results": false,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-09-06T02:52:12.011Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00011414"
    },
    {
      "nct_id": "NCT03809234",
      "title": "Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuropathic Pain"
      ],
      "interventions": [
        {
          "name": "Ondansetron 8mg with Saline & Tariquidar",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron 16mg with Saline & Tariquidar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 14,
      "start_date": "2019-05-20",
      "completion_date": "2020-11-30",
      "has_results": false,
      "last_update_posted_date": "2022-04-07",
      "last_synced_at": "2026-09-06T02:52:12.011Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03809234"
    },
    {
      "nct_id": "NCT00082368",
      "title": "PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Tariquidar",
          "type": "DRUG"
        },
        {
          "name": "Tc-94m Sestamibi",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2004-05-16",
      "completion_date": "2014-04-14",
      "has_results": true,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-09-06T02:52:12.011Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082368"
    },
    {
      "nct_id": "NCT00048633",
      "title": "Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QLT Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2001-11",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2012-05-23",
      "last_synced_at": "2026-09-06T02:52:12.011Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Vincennes, Indiana • Arlington, Texas + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Vincennes",
          "state": "Indiana"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048633"
    },
    {
      "nct_id": "NCT00001944",
      "title": "Vinorelbine and XR9576 to Treat Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Cancer",
        "Lung Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "XR9576",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "1999-12",
      "completion_date": "2001-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-09-06T02:52:12.011Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001944"
    },
    {
      "nct_id": "NCT00069160",
      "title": "Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Neoplasms",
        "Ovarian Neoplasms",
        "Cervix Neoplasms",
        "Renal Neoplasms"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "tariquidar",
          "type": "DRUG"
        },
        {
          "name": "99mTc-sestamibi imaging",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2003-09",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2012-10-12",
      "last_synced_at": "2026-09-06T02:52:12.011Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069160"
    }
  ]
}